Laidlaw lowered shares of MEI Pharma (NASDAQ:MEIP – Free Report) from a buy rating to a hold rating in a report issued on Tuesday morning, MarketBeat Ratings reports.
MEIP has been the topic of several other reports. StockNews.com began coverage on MEI Pharma in a research report on Thursday, July 18th. They set a buy rating on the stock. Stifel Nicolaus reaffirmed a hold rating and set a $7.00 price objective on shares of MEI Pharma in a research report on Friday, April 12th. Three analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $7.00.
Read Our Latest Stock Analysis on MEIP
MEI Pharma Trading Up 2.9 %
MEI Pharma (NASDAQ:MEIP – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($1.37) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.01. Equities research analysts forecast that MEI Pharma will post 3.22 earnings per share for the current fiscal year.
Hedge Funds Weigh In On MEI Pharma
An institutional investor recently bought a new position in MEI Pharma stock. Cable Car Capital LLC bought a new stake in shares of MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 611,440 shares of the company’s stock, valued at approximately $3,546,000. MEI Pharma comprises 3.9% of Cable Car Capital LLC’s holdings, making the stock its 10th largest holding. Cable Car Capital LLC owned about 9.18% of MEI Pharma as of its most recent SEC filing. 52.38% of the stock is owned by institutional investors and hedge funds.
MEI Pharma Company Profile
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Further Reading
- Five stocks we like better than MEI Pharma
- 3 Stocks to Consider Buying in October
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Breakout Stocks: What They Are and How to Identify Them
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- The 3 Best Fintech Stocks to Buy Now
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.